免疫治療薬の世界市場レポート 2025年

免疫治療薬の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.1％で4,451億2,000万米ドルに成長します。予測期間の成長は、併用療法、個別化医療、世界展開、バイオマーカー主導型治療、臨床試験の増加に起因すると考えられます。予測期間における主な動向には、免疫学の進歩、car-t細胞療法の進歩、標的免疫療法、免疫療法の併用、新抗原ワクチンなどがあります。

世界のがんの急増は、免疫療法市場における薬剤需要の高まりの主な原動力となっています。肥満、喫煙、飲酒、食習慣などの要因に起因するがん患者の急増は、著しく急増すると予測されています。2022年10月にマクミラン・キャンサー・サポートが発表したレポートでは、がん患者の急増が推定され、2025年までに350万人、2030年までに400万人、2040年までに530万人と予測されています。乳がん、肺がん、結腸がん、直腸がん、前立腺がんが最も広く蔓延しており、タバコの使用、高BMI、果物や野菜の摂取制限、飲酒、運動不足などの生活習慣が、がん関連死の約3分の1を占めています。このようながん罹患率の上昇が免疫療法薬の需要を押し上げ、結果として市場の成長を促進することになります。

ヘルスケア支出の増加は、今後の免疫療法薬市場の成長を促進すると予想されます。ヘルスケア支出とは、特定の地域や国において、一定期間内にヘルスケア商品やサービスに費やされた総額のことです。これには、医師の診察、入院、手術、診断検査、治療などの費用が含まれます。ヘルスケアに割り当てられる財源は、免疫療法薬や治療に関連する費用を賄うために、個人、医療提供者、保険会社、政府機関から提供されます。例えば、2022年12月にメディケア＆メディケイド・サービスセンターが発表したレポートによると、米国の医療費は2022年に4.1％増の4兆5,000億米ドルに達し、2021年の3.2％増を上回りました。その結果、医療費の増加が免疫治療薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界免疫治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の免疫治療薬市場：成長率分析
• 世界の免疫治療薬市場の実績：規模と成長, 2019-2024
• 世界の免疫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界免疫治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の免疫治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• インターフェロン
• インターロイキン
• ワクチン
• チェックポイント阻害剤
• その他のタイプ
• 世界の免疫治療薬市場治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん
• 自己免疫疾患と炎症性疾患
• 感染症
• その他の治療分野
• 世界の免疫治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 外来手術センター
• その他のエンドユーザー
• 世界の免疫治療薬市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 裸のモノクローナル抗体
• 結合モノクローナル抗体
• 二重特異性モノクローナル抗体
• 世界の免疫治療薬市場インターフェロンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターフェロンアルファ
• インターフェロンベータ
• インターフェロンガンマ
• 世界の免疫治療薬市場インターロイキンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターロイキン-2（IL-2）
• インターロイキン-6（IL-6）
• インターロイキン-12（IL-12）
• 世界の免疫治療薬市場、ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予防ワクチン
• 治療ワクチン
• 世界の免疫治療薬市場チェックポイント阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PD-1阻害剤
• PD-L1阻害剤
• CTLA-4阻害剤
• 世界の免疫治療薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん細胞治療
• サイトカイン療法
• T細胞受容体療法

第7章 地域別・国別分析

• 世界の免疫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の免疫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 免疫治療薬市場：競合情勢
• 免疫治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Eli Lilly and Company
• Bristol-Myers Squibb
• AstraZeneca plc
• Johnson & Johnson
• UbiVac
• Pfizer Inc.
• Sanofi SA
• Bayer AG
• Celgene Corporation
• Incyte Corporation
• Juno Therapeutics Inc.
• Bluebird bio
• Celldex Therapeutics
• BeiGene

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 免疫治療薬市場2029：新たな機会を提供する国
• 免疫治療薬市場2029：新たな機会を提供するセグメント
• 免疫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Immunotherapy drugs constitute a category of medications designed to modulate the immune system, either by enhancing or suppressing it, to bolster the body's defense against cancer, infections, and various ailments. This approach to cancer treatment harnesses the body's immune response to combat the disease.

The primary classes of immunotherapy drugs encompass monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and other specialized treatments. Monoclonal antibodies, for instance, are produced by replicating a single white blood cell, allowing the lineage of each antibody to be traced back to its originating parent cell. These drugs find application across diverse medical domains such as cancer treatment, autoimmune conditions, inflammatory diseases, and combating infections. They are employed across various healthcare settings including hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The drugs for immunotherapy market size has grown rapidly in recent years. It will grow from $255.14 billion in 2024 to $281.43 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the rising incidence of cancer, unmet medical needs, cancer immunotherapy awareness, higher adoption rates of immunotherapeutic approaches, and rising investment by pharmaceutical giants.

The drugs for immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $445.12 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to combination therapies, personalized medicine, global expansion, biomarker-driven therapies, and increasing clinical trials. Major trends in the forecast period include advancements in immunology, advancements in car-t cell therapies, targeted immunotherapies, immunotherapy combinations, and neoantigen vaccines.

The burgeoning prevalence of cancer worldwide stands as the primary impetus behind the escalating demand for drugs in the immunotherapy market. The proliferation of cancer cases, attributed to factors like obesity, smoking, alcohol consumption, and dietary habits, is projected to soar significantly. Reports from Macmillan Cancer Support in October 2022 estimated a steep rise in cancer cases, predicting 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. With breast, lung, colon, rectum, and prostate cancers ranking as the most widespread types, lifestyle elements such as tobacco use, high BMI, limited fruit and vegetable intake, alcohol consumption, and lack of exercise contribute to roughly one-third of cancer-related deaths. This escalation in cancer incidence is set to drive up the demand for immunotherapy drugs, consequently fueling market growth.

The rising healthcare expenditure is expected to drive the growth of the immunotherapy drugs market in the future. Healthcare expenditure encompasses the total amount spent on healthcare goods and services within a specific region or country over a defined period. This includes expenses for doctor visits, hospital stays, surgeries, diagnostic tests, and treatments. Financial resources allocated for healthcare come from individuals, healthcare providers, insurance companies, and government agencies to cover costs related to immunotherapy drugs and treatments. For instance, a report from the Centers for Medicare & Medicaid Services in December 2022 indicated that U.S. healthcare spending increased by 4.1% to reach $4.5 trillion in 2022, surpassing the 3.2% growth seen in 2021. As a result, the rise in healthcare expenditure is driving the growth of the drugs for immunotherapy market.

Prominent entities within the immunotherapy drugs market are strategically focused on innovating novel products such as Keytruda (pembrolizumab), aimed at delivering dependable services to consumers. Keytruda, an immune checkpoint inhibitor categorized under immunotherapy, was launched by Merck & Co., Inc. in January 2023. Approved by the US Food and Drug Administration, this breakthrough therapy assists the immune system in combating cancer cells, notably approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This development stands as a substantial leap in cancer treatment, poised to positively impact the healthcare industry's landscape.

Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilize Illumina's next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer's portfolio of assets related to allogeneic CAR-T therapy.

In December 2024, Pfizer Inc., a pharmaceutical company based in the United States, completed the acquisition of Seagen for $43 billion. This acquisition is intended to enhance Pfizer's oncology portfolio by incorporating advanced immunotherapy treatments that utilize Seagen's innovative antibody-drug conjugates (ADCs) for targeted cancer therapy. Seagen Inc. is a biotechnology firm located in the U.S. that focuses on the production of antibody-drug conjugates (ADCs).

Major companies operating in the drugs for immunotherapy market include F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, Johnson & Johnson, UbiVac, Pfizer Inc., Sanofi SA, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Gilead Sciences Inc., Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

North America was the largest region in the immunotherapy market in 2024. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drugs for Immunotherapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drugs for immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drugs for immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drugs for immunotherapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Monoclonal Antibodies; Interferons; Interleukins; Vaccines; Checkpoint Inhibitors; Other Types
• 2) By Therapy Area: Cancer; Autoimmune & Inflammatory Diseases; Infectious Diseases; Other Therapy Areas
• 3) By End User: Hospitals & Clinics; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Naked Monoclonal Antibodies; Conjugated Monoclonal Antibodies; Bispecific Monoclonal Antibodies
• 2) By Interferons: Interferon Alfa; Interferon Beta; Interferon Gamma
• 3) By Interleukins: Interleukin-2 (IL-2); Interleukin-6 (IL-6); Interleukin-12 (IL-12)
• 4) By Vaccines: Preventive Vaccines; Therapeutic Vaccines
• 5) By Checkpoint Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
• 6) By Other Types: Cancer Cell Therapies; Cytokine Therapy; T-Cell Receptor Therapy
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; Amgen Inc.; AbbVie Inc.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Drugs for Immunotherapy Market Characteristics

3. Drugs for Immunotherapy Market Trends And Strategies

4. Drugs for Immunotherapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Drugs for Immunotherapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Drugs for Immunotherapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Drugs for Immunotherapy Market Growth Rate Analysis
• 5.4. Global Drugs for Immunotherapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Drugs for Immunotherapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Drugs for Immunotherapy Total Addressable Market (TAM)

6. Drugs for Immunotherapy Market Segmentation

• 6.1. Global Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Interferons
• Interleukins
• Vaccines
• Checkpoint Inhibitors
• Other Types
• 6.2. Global Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Autoimmune & Inflammatory Diseases
• Infectious Diseases
• Other Therapy Areas
• 6.3. Global Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Other End Users
• 6.4. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Naked Monoclonal Antibodies
• Conjugated Monoclonal Antibodies
• Bispecific Monoclonal Antibodies
• 6.5. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Interferons, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferon Alfa
• Interferon Beta
• Interferon Gamma
• 6.6. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Interleukins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interleukin-2 (IL-2)
• Interleukin-6 (IL-6)
• Interleukin-12 (IL-12)
• 6.7. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Vaccines
• Therapeutic Vaccines
• 6.8. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• 6.9. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Cell Therapies
• Cytokine Therapy
• T-Cell Receptor Therapy

7. Drugs for Immunotherapy Market Regional And Country Analysis

• 7.1. Global Drugs for Immunotherapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Drugs for Immunotherapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drugs for Immunotherapy Market

• 8.1. Asia-Pacific Drugs for Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drugs for Immunotherapy Market

• 9.1. China Drugs for Immunotherapy Market Overview
• 9.2. China Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drugs for Immunotherapy Market

• 10.1. India Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drugs for Immunotherapy Market

• 11.1. Japan Drugs for Immunotherapy Market Overview
• 11.2. Japan Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drugs for Immunotherapy Market

• 12.1. Australia Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drugs for Immunotherapy Market

• 13.1. Indonesia Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drugs for Immunotherapy Market

• 14.1. South Korea Drugs for Immunotherapy Market Overview
• 14.2. South Korea Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drugs for Immunotherapy Market

• 15.1. Western Europe Drugs for Immunotherapy Market Overview
• 15.2. Western Europe Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drugs for Immunotherapy Market

• 16.1. UK Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drugs for Immunotherapy Market

• 17.1. Germany Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drugs for Immunotherapy Market

• 18.1. France Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drugs for Immunotherapy Market

• 19.1. Italy Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drugs for Immunotherapy Market

• 20.1. Spain Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drugs for Immunotherapy Market

• 21.1. Eastern Europe Drugs for Immunotherapy Market Overview
• 21.2. Eastern Europe Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drugs for Immunotherapy Market

• 22.1. Russia Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drugs for Immunotherapy Market

• 23.1. North America Drugs for Immunotherapy Market Overview
• 23.2. North America Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drugs for Immunotherapy Market

• 24.1. USA Drugs for Immunotherapy Market Overview
• 24.2. USA Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drugs for Immunotherapy Market

• 25.1. Canada Drugs for Immunotherapy Market Overview
• 25.2. Canada Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drugs for Immunotherapy Market

• 26.1. South America Drugs for Immunotherapy Market Overview
• 26.2. South America Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drugs for Immunotherapy Market

• 27.1. Brazil Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drugs for Immunotherapy Market

• 28.1. Middle East Drugs for Immunotherapy Market Overview
• 28.2. Middle East Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drugs for Immunotherapy Market

• 29.1. Africa Drugs for Immunotherapy Market Overview
• 29.2. Africa Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drugs for Immunotherapy Market Competitive Landscape And Company Profiles

• 30.1. Drugs for Immunotherapy Market Competitive Landscape
• 30.2. Drugs for Immunotherapy Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Drugs for Immunotherapy Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Eli Lilly and Company
• 31.3. Bristol-Myers Squibb
• 31.4. AstraZeneca plc
• 31.5. Johnson & Johnson
• 31.6. UbiVac
• 31.7. Pfizer Inc.
• 31.8. Sanofi SA
• 31.9. Bayer AG
• 31.10. Celgene Corporation
• 31.11. Incyte Corporation
• 31.12. Juno Therapeutics Inc.
• 31.13. Bluebird bio
• 31.14. Celldex Therapeutics
• 31.15. BeiGene

32. Global Drugs for Immunotherapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drugs for Immunotherapy Market

34. Recent Developments In The Drugs for Immunotherapy Market

35. Drugs for Immunotherapy Market High Potential Countries, Segments and Strategies

• 35.1 Drugs for Immunotherapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Drugs for Immunotherapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Drugs for Immunotherapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer